Godavari Drugs Board of Directors

Get the latest insights into the leadership at Godavari Drugs. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Ghanshyam Jaju Chairman
Mr. Mukund Kakani Managing Director
Mr. Mohit Jaju WholeTime Director & CFO
Mr. Mahendra Bhalerao Ind. Non-Executive Director
Mr. Dinesh Udpa Ind. Non-Executive Director
Mr. Syed Anis Hussain Ind. Non-Executive Director
Mrs. Vimala Behram Madon Ind. Non-Executive Director

Godavari Drugs Share price

GODAVARI

84

0.54 (0.65%)
Last updated on 4 Sep, 2025 | 15:27 IST
BUYSELL
Today's High

85.97

Today's Low

83.46

52 Week Low

79.00

52 Week High

150.95

The current prices are delayed, login to your account for live prices

Godavari Drugs FAQs

The board at Godavari Drugs consists of experienced professionals, including Mr. Ghanshyam Jaju , Mr. Mukund Kakani , and others, overseeing the company’s strategic and corporate governance.

Directors at Godavari Drugs are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Ghanshyam Jaju is the current chairman at Godavari Drugs.

Executive directors at Godavari Drugs are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Godavari Drugs adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Godavari Drugs, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.